Navigation Links
CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Date:10/27/2011

s detailed in Cardiogenesis' Securities and Exchange Commission ("SEC") filings, including its Form 10-K filing for the year ended December 31, 2010, and Cardiogenesis' other SEC filings.  Our anticipated performance for the full year of fiscal 2011 is subject to the general risks associated with our business, including that we are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product, including that a German Patent Court has nullified our main BioGlue patent in Germany, and if the ruling is upheld on appeal, we would be prevented from suing to prevent third parties from infringing the main BioGlue patent in Germany; the integration of Cardiogenesis' business into our business may be slower than expected or unsuccessful, and our revenues and operating expenses may be materially adversely impacted as a result; we are subject to stringent domestic and foreign regulation which may impede the approval process of our tissues and products, hinder our development activities and manufacturing processes, and, in some cases, result in the recall or seizure of previously cleared or approved tissues and products; our short-term liquidity and earnings in 2011 will be impacted by our substantial investment in our distribution and license and manufacturing agreements with SMI, and we may not fully realize the benefit of our investment in future years unless we are able to obtain FDA approval for PerClot in the U.S., which will require an additional commitment of funds; the FDA rejected our initial IDE application for PerClot and we are working to address its concerns, but there is no guarantee that we can do so on a timely or cost efficient basis, if at all; uncertainties related to patents and protection of proprietary technology may adversely affect the value of our intellectual property; we are involved in significant litigation with Medafor and that litigation cost may have a material adverse impact on our
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
10. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
11. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- The prevalence of cardiovascular disease in ... and changes in consumption concept, dietary habit, way of ... year, thereby promoting the development of domestic percutaneous coronary ... totaled 454,505 in 2013, up 16.9% from ... there was worth RMB20.12 billion. At present, half ...
(Date:5/27/2015)... 2015 Research and Markets ( ... "North America Portable X Ray Devices Market - ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... market for Portable X-Ray Devices is expected ... to 2020 X-Ray is a form ...
(Date:5/27/2015)... WORTH, Texas , May 27, 2015 ... defines and segments the concerned market with analysis and ... $1,017.8 million by 2019 and is estimated to grow ... 2019. Browse through the TOC of the ... idea of the in-depth analysis provided. This report also ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3
... Corporation (Nasdaq: DNDN ) announced today that ... remainder of its New Jersey manufacturing facility, allowing the ... to help meet the needs of patients with asymptomatic ... cancer.   Last April, upon receiving FDA ...
... Hospital and SynCardia Systems, Inc. announced today that Texas ... complete the first phase of certification to implant the ... use the Total Artificial Heart as a bridge to ... as children and now require mechanical support as a ...
Cached Medicine Technology:Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 2Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 3
(Date:5/27/2015)... 2015 Dr. Omar Ibrahimi, Dermatologist and ... CT has been selected as part of a controlled ... (and the only physician in Connecticut) to offer the ... the removal of submental fat (double chin). The procedure ... no surgery and minimal risks. Dr. Ibrahimi is an ...
(Date:5/27/2015)... Clearwater, Florida (PRWEB) May 27, 2015 ... accurate, impartial customer satisfaction surveys in the multiple ... user poll to determine the highest ranked Electronic ... As part of a special research focus on ... and announced those software vendors with the highest ...
(Date:5/27/2015)... Rock, AR (PRWEB) May 27, 2015 ... Medix today announce a partnership to provide CMSA's ... Medix community. This collaboration seeks to strengthen the ... measurement through CMSA’s CKP program. The mutually beneficial ... on identifying individual skills of talent in the ...
(Date:5/27/2015)... 27, 2015 Difass USA, a modern ... U.S. with its first three flagship products, Dormiva™, Relaxiva™ ... nationwide through http://www.difassusa.com . , A restful ... productivity, but some people struggle with getting the full ... a sleep aid designed to help you fall asleep ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2
... the University of Minnesota have found that cerebral malaria is related ... research is published in the current issue of the journal ... Malaria is a leading cause of death ... than 750,000 children a year, is one of the deadliest forms ...
... Mich., July 29 Stryker Corporation,(NYSE: SYK ) ... conference:, August 6, 2008 - 11:15 a.m. ... Conference New York, New York, A simultaneous ... website at http://www.stryker.com via the For Investors ...
... show that regular,monitoring of medications by physicians is ... health. Thanks to recent advances in the SMART,Registry, ... about their,patients that they never received before., ... how regularly,their chronically ill patients fill their prescriptions., ...
... developed a novel approach to treating advanced prostate cancer ... , Professor Wayne Tilley and Dr Lisa Butler of ... discovered that by using existing prostate cancer drugs in ... expect to generate better results for patients than current ...
... up in motor neurons , , TUESDAY, July 29 (HealthDay ... amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig,s ... University and Harvard Medical School. , ALS is a ... neurons in the brain and spinal cord that control ...
... the Clinical Gold Standard Drug Through 2016, According ... to a New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical and,healthcare ... has a lower discontinuation rate than that of Abbott,s,Niaspan ER ...
Cached Medicine News:Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:Stryker To Present at Investor Conference 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 3Health News:New treatment for advanced prostate cancer 2Health News:Scientists ID 'Jekyll-Hyde' Protein in Lou Gehrig's Disease 2Health News:A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: